JonesResearch initiated coverage of OnKure Therapeutics (OKUR) with a Buy rating and $32 price target. The clinical stage precision oncology ...

BeyondSpring (BYSI) has entered into definitive agreements to sell a portion of its Series A-1 Preferred Shares of SEED Therapeutics for gross ...

The global Oligonucleotide CDMO Market, valued at US$2.33 billion in 2023, is forecasted to grow at a robust CAGR of 21.8%, reaching ...

The J&J deal would be the biggest biotech deal in over a year and will add treatments for disorders of the central nervous ...

We recently published a list of 12 Stocks That Could Split in the Near Future. In this article, we are going to take a look ...

Eli Lilly has announced plans to acquire Scorpion Therapeutics ... including one involving another oncology biotech—that of the Johnson and Johnson acquiring Intracellular Therapies. Pharma and ...

We recently compiled a list of the 10 Best Stocks to Invest in According to Billionaire Cliff Asness. In this article, we are ...

With a projected revenue of USD 432.6 billion by 2032, the Oncology Cancer Drugs market is experiencing significant growth, driven by a CAGR of 9.43%. LONDON , ENGLAND, UNITED KINGDOM, January 15 ...

Ricks, Lilly chair and CEO. "The rest of our medicines performed within our expectations." "2024 was a pivotal and highly successful year for Lilly, and we expect to continue our momentum in 2025 with ...

The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Kα inhibitor currently in a Phase 1/2 clinical trial STX-478 ...

Oncology trials will outnumber CNS and cardiovascular trials, with the most planned clinical trials for 2025 are for solid tumours, followed by pain, as per the report. "Eli Lilly targets Scorpion ...

Ricks, Lilly chair and CEO. "The rest of our medicines performed within our expectations." "2024 was a pivotal and highly successful year for Lilly, and we expect to continue our momentum in ...